Clinical Cancer Research Grants Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramanathan, R. K.
Right arrow Articles by Egorin, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramanathan, R. K.
Right arrow Articles by Egorin, M. J.
Clinical Cancer Research Vol. 11, 3385-3391, May 1, 2005
© 2005 American Association for Cancer Research

Cancer Therapy: Clinical

Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers

Ramesh K. Ramanathan1,3, Donald L. Trump1,3, Julie L. Eiseman1,4, Chandra P. Belani1,3, Sanjiv S. Agarwala1,3, Eleanor G. Zuhowski1, Jing Lan1, Douglas M. Potter2, S. Percy Ivy5, Sakkaraiappan Ramalingam1,3, Adam M. Brufsky1,3, Michael K.K. Wong1,3, Susan Tutchko1 and Merrill J. Egorin1,3,4

Authors' Affiliations: 1 Molecular Therapeutics/Drug Discovery Program, 2 Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute; 3 Division of Hematology/Oncology, Departments of Medicine and 4 Pharmacology University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and 5 Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Centers, National Cancer Institute, Bethesda, Maryland

Requests for reprints: Ramesh K. Ramanathan, UPMC Cancer Pavilion, #562 5150 Center Avenue, Pittsburgh, PA 15232. Phone: 412-648-6507; Fax: 412-648-6579; E-mail: ramanathanrk{at}upmc.edu.

Purpose: 17-(Allylamino)-17-demethoxygeldanamycin (17AAG), a benzoquinone antibiotic, down-regulates oncoproteins by binding specifically to heat shock protein 90 (HSP90). We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize 17AAG pharmacokinetics and pharmacodynamics.

Experimental Design: Escalating doses of 17AAG were given i.v. over 1 or 2 hours on a weekly x 3 schedule every 4 weeks to cohorts of three to six patients. Plasma pharmacokinetics of 17AAG and 17-(amino)-17-demethoxygeldanamycin (17AG) were assessed by high-performance liquid chromatography. Expression of HSP70 and HSP90 in peripheral blood mononuclear cells was measured by Western blot.

Results: Forty-five patients were enrolled to 11 dose levels between 10 and 395 mg/m2. The maximum tolerated dose was 295 mg/m2. Dose-limiting toxicity occurred in both patients (grade 3 pancreatitis and grade 3 fatigue) treated with 395 mg/m2. Common drug-related toxicities (grade 1 and 2) were fatigue, anorexia, diarrhea, nausea, and vomiting. Reversible elevations of liver enzymes occurred in 29.5% of patients. Hematologic toxicity was minimal. No objective responses were observed. 17AAG pharmacokinetics was linear. Peak plasma concentration and area under the curve of 17AG, the active major metabolite of 17AAG, increased with 17AAG dose, but the relationships were more variable than with 17AAG. 17AAG and 17AG in plasma were >90% protein bound. There were no consistent changes in peripheral blood mononuclear cell HSP90 or HSP70 content.

Conclusions: 17AAG doses between 10 and 295 mg/m2 are well tolerated. 17AAG pharmacokinetics is linear. Peripheral blood mononuclear cell HSP90 and HSP70 are uninformative pharmacodynamic markers. The dose recommended for future studies is 295 mg/m2 weekly x 3, repeated every 4 weeks.

Key Words: clinical trial • geldanamycin • heat shock proteins • phase I study




This article has been cited by other articles:


Home page
 Anticancer ResHome page
C. MOSER, S. A. LANG, and O. STOELTZING
Heat-shock Protein 90 (Hsp90) as a Molecular Target for Therapy of Gastrointestinal Cancer
Anticancer Res, June 1, 2009; 29(6): 2031 - 2042.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
C. A. Hudis, L. M. Neckers, and D. Solit
HSP90 Inhibition for HER2-Positive Breast Cancer and Other Malignancies
Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 3 - 6.
[Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
W. W. Ma and A. A. Adjei
Novel Agents on the Horizon for Cancer Therapy
CA Cancer J Clin, March 1, 2009; 59(2): 111 - 137.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Gaspar, S. Y. Sharp, S. Pacey, C. Jones, M. Walton, G. Vassal, S. Eccles, A. Pearson, and P. Workman
Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells
Cancer Res., March 1, 2009; 69(5): 1966 - 1975.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Sreeramulu, H. R. A. Jonker, T. Langer, C. Richter, C. R. D. Lancaster, and H. Schwalbe
The Human Cdc37{middle dot}Hsp90 Complex Studied by Heteronuclear NMR Spectroscopy
J. Biol. Chem., February 6, 2009; 284(6): 3885 - 3896.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Okawa, T. Hideshima, P. Steed, S. Vallet, S. Hall, K. Huang, J. Rice, A. Barabasz, B. Foley, H. Ikeda, et al.
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
Blood, January 22, 2009; 113(4): 846 - 855.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. Banerji
Heat Shock Protein 90 as a Drug Target: Some Like It Hot
Clin. Cancer Res., January 1, 2009; 15(1): 9 - 14.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
W.-Y. Kim, D. J. Chang, B. Hennessy, H. J. Kang, J. Yoo, S.-H. Han, Y.-S. Kim, H.-J. Park, S.-Y. Geo, G. Mills, et al.
A Novel Derivative of the Natural Agent Deguelin for Cancer Chemoprevention and Therapy
Cancer Prevention Research, December 1, 2008; 1(7): 577 - 587.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. I. Heath, D. W. Hillman, U. Vaishampayan, S. Sheng, F. Sarkar, F. Harper, M. Gaskins, H. C. Pitot, W. Tan, S. P. Ivy, et al.
A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Clin. Cancer Res., December 1, 2008; 14(23): 7940 - 7946.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. N. Tse, D. S. Klimstra, M. Gonen, M. Shah, T. Sheikh, R. Sikorski, R. Carvajal, J. Mui, C. Tipian, E. O'Reilly, et al.
A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors
Clin. Cancer Res., October 15, 2008; 14(20): 6704 - 6711.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. A. Park, G. Zhang, C. Mitchell, M. Rahmani, H. Hamed, M. P. Hagan, A. Yacoub, D. T. Curiel, P. B. Fisher, S. Grant, et al.
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95
Mol. Cancer Ther., September 1, 2008; 7(9): 2633 - 2648.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. S. Ramalingam, M. J. Egorin, R. K. Ramanathan, S. C. Remick, R. P. Sikorski, T. F. Lagattuta, G. S. Chatta, D. M. Friedland, R. G. Stoller, D. M. Potter, et al.
A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies
Clin. Cancer Res., June 1, 2008; 14(11): 3456 - 3461.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Ratain and R. H. Glassman
Reply to the Letter to the Editor from Banerji et al
Clin. Cancer Res., April 15, 2008; 14(8): 2514 - 2514.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
U. Banerji, A. Affolter, I. Judson, R. Marais, and P. Workman
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors
Mol. Cancer Ther., April 1, 2008; 7(4): 737 - 739.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Zhang, A. Hamza, X. Cao, B. Wang, S. Yu, C.-G. Zhan, and D. Sun
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
Mol. Cancer Ther., January 1, 2008; 7(1): 162 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Chandarlapaty, A. Sawai, Q. Ye, A. Scott, M. Silinski, K. Huang, P. Fadden, J. Partdrige, S. Hall, P. Steed, et al.
SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers
Clin. Cancer Res., January 1, 2008; 14(1): 240 - 248.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. J. Gray Jr., M. A. Stevenson, and S. K. Calderwood
Targeting Cdc37 Inhibits Multiple Signaling Pathways and Induces Growth Arrest in Prostate Cancer Cells
Cancer Res., December 15, 2007; 67(24): 11942 - 11950.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Modi, A. T. Stopeck, M. S. Gordon, D. Mendelson, D. B. Solit, R. Bagatell, W. Ma, J. Wheler, N. Rosen, L. Norton, et al.
Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2 Overexpressing Breast Cancer: A Phase I Dose-Escalation Study
J. Clin. Oncol., December 1, 2007; 25(34): 5410 - 5417.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
Y. Niikura, A. Dixit, R. Scott, G. Perkins, and K. Kitagawa
BUB1 mediation of caspase-independent mitotic death determines cell fate
J. Cell Biol., July 10, 2007; 178(2): 283 - 296.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. H. Oh, J. K. Woo, Y. D. Yazici, J. N. Myers, W.-Y. Kim, Q. Jin, S. S. Hong, H.-J. Park, Y.-G. Suh, K.-W. Kim, et al.
Structural Basis for Depletion of Heat Shock Protein 90 Client Proteins by Deguelin
J Natl Cancer Inst, June 20, 2007; 99(12): 949 - 961.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Eiseman, J. Guo, R. K. Ramanathan, C. P. Belani, D. B. Solit, H. I. Scher, S. P. Ivy, E. G. Zuhowski, and M. J. Egorin
Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors
Clin. Cancer Res., April 1, 2007; 13(7): 2121 - 2127.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. K. Ramanathan, M. J. Egorin, J. L. Eiseman, S. Ramalingam, D. Friedland, S. S. Agarwala, S. P. Ivy, D. M. Potter, G. Chatta, E. G. Zuhowski, et al.
Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers
Clin. Cancer Res., March 15, 2007; 13(6): 1769 - 1774.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. B. Solit, S. P. Ivy, C. Kopil, R. Sikorski, M. J. Morris, S. F. Slovin, W. K. Kelly, A. DeLaCruz, T. Curley, G. Heller, et al.
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer
Clin. Cancer Res., March 15, 2007; 13(6): 1775 - 1782.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Bagatell, L. Gore, M. J. Egorin, R. Ho, G. Heller, N. Boucher, E. G. Zuhowski, J. A. Whitlock, S. P. Hunger, A. Narendran, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study
Clin. Cancer Res., March 15, 2007; 13(6): 1783 - 1788.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Stellas, A. Karameris, and E. Patsavoudi
Monoclonal Antibody 4C5 Immunostains Human Melanomas and Inhibits Melanoma Cell Invasion and Metastasis
Clin. Cancer Res., March 15, 2007; 13(6): 1831 - 1838.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
E. Kamynina, K. Kauppinen, F. Duan, N. Muakkassa, and D. Manor
Regulation of Proto-Oncogenic Dbl by Chaperone-Controlled, Ubiquitin-Mediated Degradation
Mol. Cell. Biol., March 1, 2007; 27(5): 1809 - 1822.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Mitchell, M. A. Park, G. Zhang, S. I. Han, H. Harada, R. A. Franklin, A. Yacoub, P.-L. Li, P. B. Hylemon, S. Grant, et al.
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines
Mol. Cancer Ther., February 1, 2007; 6(2): 618 - 632.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
W. Lang, G. W. Caldwell, J. Li, G. C. Leo, W. J. Jones, and J. A. Masucci
Biotransformation of Geldanamycin and 17-Allylamino-17-Demethoxygeldanamycin by Human Liver Microsomes: Reductive versus Oxidative Metabolism and Implications
Drug Metab. Dispos., January 1, 2007; 35(1): 21 - 29.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. K. McCollum, C. J. TenEyck, B. M. Sauer, D. O. Toft, and C. Erlichman
Up-regulation of Heat Shock Protein 27 Induces Resistance to 17-Allylamino-Demethoxygeldanamycin through a Glutathione-Mediated Mechanism.
Cancer Res., November 15, 2006; 66(22): 10967 - 10975.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Lou, N. Fatima, Z. Xiao, S. Stauffer, G. Smythers, P. Greenwald, and I. U. Ali
Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells.
Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1598 - 1606.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
L. Chin, L. A. Garraway, and D. E. Fisher
Malignant melanoma: genetics and therapeutics in the genomic era.
Genes & Dev., August 15, 2006; 20(16): 2149 - 2182.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
B. Gyurkocza, J. Plescia, C. M. Raskett, D. S. Garlick, P. A. Lowry, B. Z. Carter, M. Andreeff, M. Meli, G. Colombo, and D. C. Altieri
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
J Natl Cancer Inst, August 2, 2006; 98(15): 1068 - 1077.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
P. M. Smith-Jones, D. Solit, F. Afroze, N. Rosen, and S. M. Larson
Early Tumor Response to Hsp90 Therapy Using HER2 PET: Comparison with 18F-FDG PET
J. Nucl. Med., May 1, 2006; 47(5): 793 - 796.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. J. Pienta and D. Bradley
Mechanisms underlying the development of androgen-independent prostate cancer.
Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671.
[Full Text] [PDF]

Home page
 BloodHome page
C. S. Mitsiades, N. S. Mitsiades, C. J. McMullan, V. Poulaki, A. L. Kung, F. E. Davies, G. Morgan, M. Akiyama, R. Shringarpure, N. C. Munshi, et al.
Antimyeloma activity of heat shock protein-90 inhibition
Blood, February 1, 2006; 107(3): 1092 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty and K. I. Block
Multifocal Angiostatic Therapy: An Update
Integr Cancer Ther, December 1, 2005; 4(4): 301 - 314.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
N. O. Ibrahim, T. Hahn, C. Franke, D. P. Stiehl, R. Wirthner, R. H. Wenger, and D. M. Katschinski
Induction of the Hypoxia-Inducible Factor System by Low Levels of Heat Shock Protein 90 Inhibitors
Cancer Res., December 1, 2005; 65(23): 11094 - 11100.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. Banerji, M. Walton, F. Raynaud, R. Grimshaw, L. Kelland, M. Valenti, I. Judson, and P. Workman
Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models
Clin. Cancer Res., October 1, 2005; 11(19): 7023 - 7032.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.